

Apixaban (Eliquis) Drug Level

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

[Effective Date](#) 4/2019
[Next Review Date](#) 6/2024
[Coverage Policy](#) Medical 303
[Version](#) 3

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details*.

Purpose:

This policy addresses the medical necessity of Apixaban (Eliquis) Drug Level.

Description & Definitions:

Apixaban Drug Level testing the level of a direct oral anticoagulant (DOAC) medication in the blood stream.

Criteria:

Apixaban (Eliquis) Drug Level is considered not medically necessary for any indication.

Coding:

Medically necessary with criteria:

Coding	Description
	None

Considered Not Medically Necessary:

Coding	Description
80299	Quantitation of therapeutic drug, not elsewhere specified.

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

Reviewed Dates:

- 2023: June

Medical 303

- 2022: June
- 2021: August
- 2020: August

Effective Date:

- April 2019

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Leveraging Quantitative Methods in Reviewing Complex/Locally Acting Products. US Food and Drug Administration. (10.2.2017). Retrieved 6.13.2023. <https://www.fda.gov/media/108570/download>

(2023). Apixaban (Eliquis) Drug Level. Hayes, a symplr company. (2023). Retrieved 6.13.2023. https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Apixaban%2520Drug%2520Level%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%2522sources%2522:%255B%2522%2522%255D,%2522sorts%2522:%255B%257B%2522field%2522:%2522_score%2522,%2522direction%2522:%2522desc%2522%257D%255D,%2522filters%2522:%255B%255D%257D

(2023). MCG, Informed Care Strategies. (2023). Retrieved 6.13.2023. <https://careweb.careguidelines.com/ed26/index.html>

(2023). Centers for Medicare and Medicaid Services. CMS.gov. Retrieved 6.13.2023. <https://www.cms.gov/medicare-coverage-database/search-results.aspx?keyword=apixaban%20drug%20level&keywordType=starts&areald=all&docType=6,3,5,1,F,P&contractOption=all&hcpcsOption=code&hcpcsStartCode=82777&hcpcsEndCode=82777&sortBy=title>

(2023). Procedure Fee Files & CPT Codes. Virginia's Medicaid Program. Department of Medical Assistance Services. An Agency of the Commonwealth of Virginia. Retrieved 6.13.2023. <https://www.dmas.virginia.gov/providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/#searchCPT>

(2023). Avalon Optima Health Laboratory Testing Policies. (2023). Retrieved 6.13.2023. <https://www.avalonhcs.com/policies-optimahealth/>

(2023). Jakowenko, N., Nguyen, S., Ruegger, M., Dinh, A., Salazar, R., Donahue, K. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thrombosis Research. (9.6.2020). PubMed. National Library of Medicine. Retrieved 6.13.2023. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474843/#:~:text=Expected%20peak%20levels%20for%20apixaban,and%205%20mg%20dose%2C%20respectively.>

(2023). American Society of Hematology. (2023). Retrieved 6.13.2023. <https://www.hematology.org/searchresults#?cludoquery=anticoagulant%20apixaban%20superior%20to%20warfarin%20for%20reducing%20brain%20bleeds%20in%20patients%20with%20atrial%20fibrillation&cludopage=1&cludorefurl=https%3A%2F%2Fwww.hematology.org%2Feducation&cludorefpt=Education%20-%20Hematology.org&cludorefact=apix&cludorefaci=1&cludoinputtype=standard>

Anticoagulant Therapy for Pulmonary Embolism. (2022, Apr 11). Retrieved Jun 07, 2022, from DynaMed: <https://www.dynamedex.com/management/anticoagulant-therapy-for-pulmonary-embolism#GUID-1FF2B018-7E0B-4869-A8DF-33FC63B7E0A8>

Leung, L. (2022, May 12). Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects. Retrieved Jun 07, 2022, from UpToDate: <https://www.uptodate.com/contents/direct-oral-Medical-303>

anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?search=apixaban&source=search_result&selectedTitle=3~149&usage_type=default&display_rank=2#H5818288

Reda, S., Rudde, E., Muller, J., Hamedani, N., Oldenburg, J., Potzsch, B., & Ruhl, H. (2022, May 08). Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism. Retrieved Jun 07, 2022, from PubMed:
<https://pubmed.ncbi.nlm.nih.gov/?term=Therapeutic+day+treatment+for+youth&filter=simsearch1.fha&filter=simsearch2.frrft&filter=years.2022-2022>

Special Notes: *

This medical policy expresses Sentara Health Plan's determination of medical necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Keywords:

SHP Apixaban Drug Level, SHP Medical 303, blood test, Eliquis